Cholangiocarcinoma and its management.
作者信息
Khan S A, Miras A, Pelling M, Taylor-Robinson S D
机构信息
Faculty of Medicine, Imperial College London, St Mary's Hospital Campus, London, UK.
出版信息
Gut. 2007 Dec;56(12):1755-6. doi: 10.1136/gut.2007.138859.
Abstract
摘要
相似文献
1
Cholangiocarcinoma and its management.胆管癌及其治疗
Gut. 2007 Dec;56(12):1755-6. doi: 10.1136/gut.2007.138859.
2
[Diagnosis and treatment of cholangiocarcinoma].[胆管癌的诊断与治疗]
Korean J Hepatol. 2005;11 Suppl 1:48-58.
3
[Medical management of cholangiocarcinoma].
Gastroenterol Clin Biol. 2004 Jan;28(1):57-65. doi: 10.1016/s0399-8320(04)94842-7.
4
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma.肝内胆管癌诊断和管理指南
J Hepatol. 2014 Jun;60(6):1268-89. doi: 10.1016/j.jhep.2014.01.021. Epub 2014 Mar 27.
5
In Reply.作为回复。
Dtsch Arztebl Int. 2015 May 25;112(21-22):373. doi: 10.3238/arztebl.2015.0373.
6
[The current status and future problems related to management of cholangiocarcinoma].
Nihon Shokakibyo Gakkai Zasshi. 2010 Jul;107(7):1109-26.
7
Radioembolization as a Treatment Option.放射性栓塞作为一种治疗选择。
Dtsch Arztebl Int. 2015 May 25;112(21-22):372-3. doi: 10.3238/arztebl.2015.0372b.
8
[Cholangiocarcinoma].[胆管癌]
Internist (Berl). 1997 Oct;38(10):970-6. doi: 10.1007/s001080050108.
9
Recent advances in the management of cholangiocarcinomas.胆管癌治疗的最新进展
Semin Liver Dis. 1994 May;14(2):109-14. doi: 10.1055/s-2007-1007302.
10
Evidence-based approach to cholangiocarcinoma: a systematic review of the current literature.胆管癌的循证医学方法：对当前文献的系统综述
J Am Coll Surg. 2009 Jan;208(1):134-47. doi: 10.1016/j.jamcollsurg.2008.09.007. Epub 2008 Oct 31.
引用本文的文献
1
Identifying a unique chromosomal pattern to predict the gemcitabine response in patients with cholangiocarcinoma.识别一种独特的染色体模式以预测胆管癌患者对吉西他滨的反应。
Sci Rep. 2025 Apr 8;15(1):11984. doi: 10.1038/s41598-025-96442-4.
2
Liver Flukes: Clonorchis and Opisthorchis.肝吸虫：华支睾吸虫和异形吸虫。
Adv Exp Med Biol. 2024;1454:239-284. doi: 10.1007/978-3-031-60121-7_7.
3
Prognostic influence for hilar cholangiocarcinoma and comparisons of prognostic values of Mayo staging and TNM staging systems.肝门部胆管癌的预后影响及 Mayo 分期和 TNM 分期系统预后价值的比较。
Medicine (Baltimore). 2022 Dec 9;101(49):e32250. doi: 10.1097/MD.0000000000032250.
4
Usefulness of serum microRNA as a predictive marker of recurrence and prognosis in biliary tract cancer after radical surgery.血清 microRNA 作为根治性手术后胆道癌复发和预后的预测标志物的实用性。
Sci Rep. 2019 Apr 11;9(1):5925. doi: 10.1038/s41598-019-42392-7.
5
Identification of a serum biomarker panel for the differential diagnosis of cholangiocarcinoma and primary sclerosing cholangitis.用于鉴别诊断胆管癌和原发性硬化性胆管炎的血清生物标志物组的鉴定
Oncotarget. 2018 Apr 3;9(25):17430-17442. doi: 10.18632/oncotarget.24732.
6
Clustering of patients with intrahepatic cholangiocarcinoma based on serum periostin may be predictive of prognosis.基于血清骨膜蛋白对肝内胆管癌患者进行聚类分析可能有助于预测预后。
Oncol Lett. 2017 Jul;14(1):623-634. doi: 10.3892/ol.2017.6250. Epub 2017 May 25.
7
Kaempferol inhibits the growth and metastasis of cholangiocarcinoma in vitro and in vivo.山奈酚在体外和体内均抑制胆管癌的生长和转移。
Acta Biochim Biophys Sin (Shanghai). 2016 Mar;48(3):238-45. doi: 10.1093/abbs/gmv133. Epub 2016 Feb 15.
8
MicroRNA-144 suppresses cholangiocarcinoma cell proliferation and invasion through targeting platelet activating factor acetylhydrolase isoform 1b.微小RNA-144通过靶向血小板活化因子乙酰水解酶1b亚型抑制胆管癌细胞的增殖和侵袭。
BMC Cancer. 2014 Dec 5;14:917. doi: 10.1186/1471-2407-14-917.
9
Update on the management of cholangiocarcinoma.胆管癌管理的最新进展。
Dig Dis. 2014;32(5):570-8. doi: 10.1159/000360507. Epub 2014 Jul 14.
10
Aberrant DNA methylation at genes associated with a stem cell-like phenotype in cholangiocarcinoma tumors.胆管癌肿瘤中与干细胞样表型相关的基因的异常 DNA 甲基化。
Cancer Prev Res (Phila). 2013 Dec;6(12):1348-55. doi: 10.1158/1940-6207.CAPR-13-0104. Epub 2013 Oct 2.
本文引用的文献
1
Liver transplantation for unresectable perihilar cholangiocarcinoma.不可切除性肝门部胆管癌的肝移植治疗
Semin Liver Dis. 2004 May;24(2):201-7. doi: 10.1055/s-2004-828896.
2
The epidemiology of cholangiocarcinoma.胆管癌的流行病学
Semin Liver Dis. 2004 May;24(2):115-25. doi: 10.1055/s-2004-828889.
3
Diagnosis and treatment of cholangiocarcinoma.胆管癌的诊断与治疗
Oncologist. 2004;9(1):43-57. doi: 10.1634/theoncologist.9-1-43.
4
Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer.每周使用吉西他滨治疗胆管癌和胆囊癌。
Invest New Drugs. 2004 Apr;22(2):193-8. doi: 10.1023/B:DRUG.0000011797.09549.53.
5
Changing international trends in mortality rates for liver, biliary and pancreatic tumours.肝脏、胆道和胰腺肿瘤死亡率的国际趋势变化
J Hepatol. 2002 Dec;37(6):806-13. doi: 10.1016/s0168-8278(02)00297-0.
6
Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document.胆管癌诊疗指南：共识文件
Gut. 2002 Nov;51 Suppl 6(Suppl 6):VI1-9. doi: 10.1136/gut.51.suppl_6.vi1.
7
Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States.美国原发性肝内胆管癌的发病率和死亡率不断上升。
Hepatology. 2001 Jun;33(6):1353-7. doi: 10.1053/jhep.2001.25087.
8
Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998.1968年至1998年英格兰和威尔士肝内胆管癌死亡率的上升。
Gut. 2001 Jun;48(6):816-20. doi: 10.1136/gut.48.6.816.
9
Unilateral versus bilateral endoscopic hepatic duct drainage in patients with malignant hilar biliary obstruction: results of a prospective, randomized, and controlled study.单侧与双侧内镜下肝管引流治疗恶性肝门部胆管梗阻患者：一项前瞻性、随机对照研究的结果
Gastrointest Endosc. 2001 May;53(6):547-53. doi: 10.1067/mge.2001.113381.
10
Imaging techniques in patients with biliary obstruction.胆管梗阻患者的成像技术。
Med Sci Monit. 2000 Nov-Dec;6(6):1197-202.
Zotero 插件